# A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors

> **NCT07669415** · PHASE2 · RECRUITING · sponsor: **LaNova Medicines Limited** · enrollment: 108 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** LM-168
- **DRUG:** Tislelizumab
- **DRUG:** Docetaxel injection

## Key facts

- **NCT ID:** NCT07669415
- **Lead sponsor:** LaNova Medicines Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-29
- **Primary completion:** 2027-12-15
- **Final completion:** 2028-12-15
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2026-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07669415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07669415, "A Study of LM-168 Combined With Other Anti-tumor Treatments in Participants With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07669415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*